Ask My Investor AI
Public company · ASX and NasdaqPublished company research
TLX

Official issuer releases identify Telix Pharmaceuticals Limited as a dual-listed commercial-stage radiopharmaceutical company (ASX and Nasdaq: TLX) reporting its reviewed operating results in U.S. dollars.

Telix Pharmaceuticals Limited

Telix is a direct radiopharmaceutical operating company rather than an incidental isotope exposure. Q2 2026 group revenue was US$247M, including US$202M from Precision Medicine and US$45M from Telix Manufacturing Solutions. Its commercial PSMA imaging products, U.S. radiopharmacy network and manufacturing footprint provide direct exposure to time-sensitive isotope production and distribution. The therapeutic pipeline adds upside but also clinical and regulatory risk. No price or entry conclusion is permitted without licensed current valuation and human review.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
TLX
Exchange
ASX and Nasdaq
HQ
Australia
Currency
USD
SEC CIK
Non-SEC filer
Investment case

How this company captures the theme economics

Competitive position

The company combines commercial diagnostic products, a U.S. radiopharmacy network, manufacturing sites and a therapeutic pipeline. Official Q2 reporting attributes growth to Illuccix and Gozellix demand and describes supply-chain resilience as a competitive factor; however, durable market share, manufacturing economics and isotope self-sufficiency still require independent review.

Scarce assets

A radiopharmacy and manufacturing network able to prepare and deliver short-lived radiopharmaceutical doses; regulated product authorizations; production and development sites; and a pipeline spanning diagnostic and therapeutic radiopharmaceuticals.

Products, segments, and customers

Precision Medicine commercializes Illuccix and Gozellix PSMA imaging products. Telix Manufacturing Solutions includes the RLS radiopharmacy network and production capabilities. Telix Therapeutics advances radiopharmaceutical candidates including TLX591-Tx and TLX250-Tx.

Theme capture

High and direct. Q2 2026 Precision Medicine revenue represented US$202M of US$247M group revenue, while TMS contributed US$45M. The enterprise's products, manufacturing and distribution activities are all within the medical-isotope and radiopharmaceutical value chain.

Conditions

What must be true

  1. Commercial PSMA imaging dose growth and pricing remain durable while Gozellix scales alongside Illuccix.
  2. The expanded manufacturing and radiopharmacy footprint improves reliability and margins rather than adding structurally underutilized fixed cost.
  3. Late-stage therapeutic programs meet clinical, regulatory and manufacturing requirements.

Identifiable catalysts

  • Further commercial dose-volume growth and product approvals in additional jurisdictions.
  • Regulatory and enrollment progress for ProstACT Global and other late-stage programs.
  • Evidence that manufacturing and radiopharmacy integration improves supply reliability and financial performance.
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Radiopharmaceutical products, regulated manufacturing and short-half-life pharmacy distribution.

Medical isotopes and radiopharmaceutical logistics

Direct and group-level. Q2 2026 group revenue was US$247M, with US$202M from Precision Medicine and US$45M from TMS; official reporting ties commercial growth to Illuccix and Gozellix and describes an integrated manufacturing and pharmacy-distribution model.

Evidence
Official Q2 2026 and FY2025 issuer releases directly support product, segment, network and reported financial claims. Pipeline products remain subject to clinical and regulatory risk, and current valuation is unavailable.
Materiality
disclosed — The company reports Precision Medicine and TMS revenue separately, and both segments are directly within the radiopharmaceutical value chain. This establishes theme materiality at enterprise scale without estimating undisclosed product margins.
Financial evidence

Official public disclosures

Reference period: Q2 2026 and FY2025.

  • Group revenueUS$247M; +21% year over year
    Q2 2026[1]
  • Precision Medicine revenueUS$202M; +30% year over year
    Q2 2026[1]
  • Telix Manufacturing Solutions revenueUS$45M
    Q2 2026[1]
  • Group revenueUS$803.8M
    FY2025[2]
  • Adjusted EBITDAUS$39.5M
    FY2025[2]

Limitation: Q2 figures are unaudited, therapeutic pipeline value is not realized revenue, and licensed current valuation is unavailable. Product-level margins and isotope-supply economics are not fully disclosed.

Risks

Material risks and break conditions

Material risks

  • Clinical or regulatory failure in pivotal therapeutic programs.
  • Manufacturing, isotope-supply or time-critical distribution disruption.
  • Commercial concentration in PSMA imaging and reimbursement or competitive pressure.
  • High R&D investment and acquisition integration could reduce cash generation.

Thesis-break conditions

  • Sustained decline in commercial dose volumes or Precision Medicine revenue.
  • Material manufacturing or distribution failures that impair reliable dose delivery.
  • Repeated pivotal-program failures that remove the therapeutic growth leg.
Investability conclusion

Where the evidence lands

Telix has directly supported, financially material exposure to medical isotopes through commercial radiopharmaceutical products, manufacturing and distribution. The company remains NOT_READY because current valuation, product-level economics, supply resilience and human acceptance are unresolved.

Next diligence

  1. Obtain licensed current valuation and compare it with cash generation and pipeline-adjusted scenarios.
  2. Verify isotope sourcing, network utilization and product-level gross-margin durability.
  3. Review pivotal trial designs and regulatory timelines without assigning unsupported probability-of-success.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Q2 2026 Revenue US$247M Strong Momentum Pipeline ProgressTelix Pharmaceuticals Limited · primary · published 2026-07-21 · accessed 2026-07-29
  2. FY 2025 Results: Strong Commercial Growth, Focused Pipeline InvestmentTelix Pharmaceuticals Limited · primary · published 2026-02-20 · accessed 2026-07-29